KAPA

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all patients in the trial treated with ENV-105 plus apalutamide and those treated with apalutamide alone. Median PFS was 17.7 months with the combination compared with 2 months with apalutamide alone (P=0.0008). With the interim efficacy sig

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference’s website. Bhowmick will moderate an in-person only breakout session on Sept. 30 titled, "Winning the Race against Cancer Therapy Resistance," focused on Kairos’ primary strategy of targeting cancer drug resistance for patients with high unmet need in o

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Presentation Date: September 14, 2026 Time: 4:00 PM Eastern Time (Holmes 1) Webcast Link: Available Here A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A replay of the webcast will be archived and available following the event for 90 days. Dr. Yu will be av

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the "Effective Time"), with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol "KAPA" and a new CUSIP number of 48301N203. In connection with the Reverse Stock Split, every seven (7) shares of the Company’s common stock issued an

10-Q - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

Combination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer’s XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. Kairos Pharma’s current programs with ENV-105 include a Phase 1 trial in EGFR-driven non-small cell lung cancer and a Phase 2 trial for castr

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

DEFA14A - Kairos Pharma, LTD. (0001962011) (Filer)

DEF 14A - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)

Company selected for the Leaders in Drug Resistance Development award Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as the Leaders in Drug Resistance Development 2026 - USA award recipient. Following a merit-led research and evaluation process by GHP's expert research and judging team, based on innovation, impact, business performance and contribution to patient outcomes, Kairos Pharma has been recognized as a leader in the research and development to combat drug resistance. "Drug resistance can no longer be an af

10-Q - Kairos Pharma, LTD. (0001962011) (Filer)

PRE 14A - Kairos Pharma, LTD. (0001962011) (Filer)

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on Monday, June 29, 2026. After the meeting materials are finalized and filed with the Securities and Exchanges Commission, such materials will be mailed to shareholders. The Company also advises its Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2025, contained an audit report from its Independent Registered Public Accounting Firm with an explanatory paragraph emphasizing that the Consolidated Financial Statements were prepared assuming

Company selected as an Emerald honoree for Innovator of Biotech Solutions Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the 2026 Pinnacle Awards for Healthcare, being selected as an Emerald honoree for Innovator of Biotech Solutions for addressing cancer drug resistance. Kairos Pharma was recognized for its differentiated approach to targeting the biological mechanisms that allow tumors to evade treatment. Rather than developing standalone therapies, Kairos is advancing resistance-modulating treatments designed to restore and extend the effectiveness of existing cancer th

424B3 - Kairos Pharma, LTD. (0001962011) (Filer)

424B3 - Kairos Pharma, LTD. (0001962011) (Filer)

10-K - Kairos Pharma, LTD. (0001962011) (Filer)

8-K - Kairos Pharma, LTD. (0001962011) (Filer)